IMRAN MIR A 4
4 · Rani Therapeutics Holdings, Inc. · Filed Jun 1, 2026
Research Summary
AI-generated summary of this filing
Rani Therapeutics (RANI) 10% Owner Imran Mir Receives Option Award
What Happened Imran Mir, listed as a 10% owner of Rani Therapeutics (RANI), was granted a derivative award on 2026-05-28 covering 123,600 shares. The award shows an acquisition price of $0.00 (no cash paid at grant) and is reported as an award/grant (transaction code A). This is a grant of an option-like award rather than an open-market purchase or sale.
Key Details
- Transaction date: 2026-05-28; Form 4 filed 2026-06-01.
- Amount: 123,600 shares granted; reported acquisition price $0.00; total reported cash value $0.
- Vesting: Per footnote, the shares subject to the option vest in full on the first anniversary of the grant subject to continuous service, or earlier upon the company's next annual stockholder meeting or a Change in Control.
- Shares owned after transaction: Not stated in the filing.
- Transaction type: Derivative award (grant of option/option-like award). No immediate exercise or sale reported.
Context This filing reports an award (grant) rather than a purchase or sale, so it does not represent immediate market buying or selling. The award vests in the future and may accelerate on defined corporate events; therefore no shares were necessarily transferable or sold at the time of the report. As a reported 10% owner, Imran Mir is a significant shareholder—this is insider reporting of a compensation/ownership grant, not a routine open-market trade.
Insider Transaction Report
- Award
Director Stock Option (Right to Buy)
[F1]2026-05-28+123,600→ 123,600 totalExercise: $0.95Exp: 2036-05-27→ Class A Common Stock (123,600 underlying)
Footnotes (1)
- [F1]The shares subject to the option vest in full on the first anniversary of the date of grant, subject to the Reporting Person's Continuous Service (as defined in the Company's 2021 Equity Incentive Plan (the "2021 Plan")) through such vesting date; provided that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Company's next annual stockholder meeting or a Change in Control (as defined in the 2021 Plan), each subject to the Reporting Person's Continuous Service through such date.